Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 27:10:1221846.
doi: 10.3389/fmed.2023.1221846. eCollection 2023.

Advances in multi-modal non-invasive imaging techniques in the diagnosis and treatment of polypoidal choroidal vasculopathy

Affiliations
Review

Advances in multi-modal non-invasive imaging techniques in the diagnosis and treatment of polypoidal choroidal vasculopathy

Yuelin Wang et al. Front Med (Lausanne). .

Abstract

Polypoidal choroidal vasculopathy (PCV) is a disease characterized by subretinal pigment epithelium (RPE) orange-red polypoidal lesions and abnormal branching neovascular networks (BNNs). In recent years, various non-invasive imaging technologies have rapidly developed, especially the emergence of optical coherence tomography angiography (OCTA), multi-spectral imaging, and other technologies, which enable the observation of more features of PCV. In addition, these technologies are faster and less invasive compared to indocyanine green angiography (ICGA). Multi-modal imaging, which combined multiple imaging techniques, provides important references for the diagnosis and treatment of PCV with the assistance of regression models, deep learning, and other algorithms. In this study, we reviewed the non-invasive imaging techniques, multi-modal imaging diagnosis, and multi-scene therapeutic applications of PCV, with the aim of providing a reference for non-invasive multi-modal diagnosis and treatment of PCV.

Keywords: diagnosis; multimodal; non-invasive imaging technology; polypoidal choroidal vasculopathy (PCV); treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Sen P, Manayath G, Shroff D, Salloju V, Dhar P. Polypoidal choroidal vasculopathy: an update on diagnosis and treatment. Clin Ophthalmol. (2023) 17:53–70. 10.2147/OPTH.S385827 - DOI - PMC - PubMed
    1. Koh AH, Expert PCVP, Chen LJ, Chen SJ, Chen Y, Giridhar A, et al. . Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment. Retina. (2013) 33:686–716. 10.1097/IAE.0b013e3182852446 - DOI - PubMed
    1. Xue Y, Qinhua C. Short-term efficacy in polypoidal choroidal vasculopathy patients treated with intravitreal aflibercept or conbercept. Front Med (Lausanne). (2022) 9:835255. 10.3389/fmed.2022.835255 - DOI - PMC - PubMed
    1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina (Philadelphia, Pa). (1990) 10:1–8. 10.1097/00006982-199001010-00001 - DOI - PubMed
    1. Han J, Choi S, Park JI, Hwang JS, Han JM, Ko J, et al. . Detecting macular disease based on optical coherence tomography using a deep convolutional network. J Clin Med. (2023) 12:1005. 10.3390/jcm12031005 - DOI - PMC - PubMed

LinkOut - more resources